A proof-of-concept study of VK-2809 for the treatment of glycogen storage disease type Ia (GSD Ia)

Trial Profile

A proof-of-concept study of VK-2809 for the treatment of glycogen storage disease type Ia (GSD Ia)

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Glycogen storage disease type I
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 17 Feb 2017 New trial record
    • 14 Feb 2017 According to a Viking Therapeutics media release, the company plans to to file an Investigational New Drug (IND) application for VK2809 for the treatment of GSD Ia and initiate this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top